Organoid quality is assessed across multiple parameters to ensure batch-to-batch consistency and reliable experimental performance. Key criteria include organoid size and morphology, tissue-specific marker expression, and functional characteristics . ACROBiosystems applies comprehensive quality control to each batch and provides a Certificate of Analysis (COA) with clear quality documentation. These measures help support consistent organoid performance in preclinical drug screening and safety studies.

ACROBiosystems provides a range of recombinant B7-H3 (CD276) proteins designed for different research workflows, including antibody screening, binding characterization, ADC discovery, and cell-based studies. Available formats include B7-H3 (2Ig) and (4Ig), different tag configurations, biotinylated and fluorescently labeled proteins, as well as B7-H3-expressing cell-lines, enabling researchers to select formats according to their experimental requirements.

Biotinylated B7-H3 proteins are suited to streptavidin-based capture or detection systems, while fluorescently labeled proteins enable direct fluorescence-based detection, including flow cytometry. Selection should match the assay readout and detection strategy. ACROBiosystems provides multiple labeled B7-H3 formats for different assay requirements.

B7-H3 protein selection can be matched to the location and structural dependence of the antibody epitope. B7-H3 (4Ig) may be considered when recognition depends on a more complete extracellular structure, while shorter constructs may be suitable for epitopes within the corresponding region. ACROBiosystems provides different B7-H3 extracellular domain formats for these characterization needs.

The appropriate B7-H3 format depends on the assay and detection strategy. His-tagged proteins are commonly used for SPR, BLI, and ELISA-based binding studies, while Fc-tagged proteins can be useful for assays requiring an Fc-mediated detection or immobilization strategy. Biotinylated B7-H3 proteins provide an alternative for streptavidin-based assay formats. For antibody screening against the native extracellular region, a full-length extracellular B7-H3 (4Ig) format can be considered when the target epitope may depend on the complete domain structure.

B7-H3 exists in isoforms containing either two or four Ig-like domains in the extracellular region. B7-H3 (4Ig) contains the full extracellular domain and is commonly used when a more complete representation of the native extracellular structure is required, while B7-H3 (2Ig) provides a shorter extracellular format for applications where a more compact construct is preferred. The appropriate format should be selected based on the target epitope, assay design, and intended application.